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Abstract
Background: Reproductive events are associated with important physiologic changes, yet little is known about
how reproductive factors influence long-term health in women. Our objective was to assess the relation of reproductive
characteristics with all-cause and cause-specific mortality risk.
Methods: The analysis was performed within the European Investigation into Cancer and Nutrition prospective cohort
study, which enrolled >500,000 women and men from 1992 to 2000, who were residing in a given town/geographic
area in 10 European countries. The current analysis included 322,972 eligible women aged 25–70 years with 99 %
complete follow-up for vital status. We assessed reproductive characteristics reported at the study baseline including
parity, age at the first birth, breastfeeding, infertility, oral contraceptive use, age at menarche and menopause, total
ovulatory years, and history of oophorectomy/hysterectomy. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for
mortality were determined using Cox proportional hazards regression models adjusted for menopausal status, body
mass index, physical activity, education level, and smoking status/intensity and duration.
Results: During a mean follow-up of 12.9 years, 14,383 deaths occurred. The HR (95 % CI) for risk of all-cause mortality
was lower in parous versus nulliparous women (0.80; 0.76–0.84), in women who had ever versus never breastfed
(0.92; 0.87–0.97), in ever versus never users of oral contraceptives (among non-smokers; 0.90; 0.86–0.95), and in
women reporting a later age at menarche (≥15 years versus <12; 0.90; 0.85–0.96; P for trend = 0.038).
Conclusions: Childbirth, breastfeeding, oral contraceptive use, and a later age at menarche were associated with
better health outcomes. These findings may contribute to the development of improved strategies to promote
better long-term health in women.
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Background
Reproductive events represent significant biological mile-
stones in a woman’s life and are associated with profound
physiologic and endocrinologic changes. It is recognized
that reproductive factors influence the risk of developing
reproductive-related cancers; for example, age at menar-
che, use of oral contraceptives (OCs), parity, breastfeeding,
and age at menopause are associated with risk of develop-
ing cancers of the breast, endometrium, and ovary [1–3].
Analyses of reproductive parameters in relation to all-
cause and cause-specific mortality risk can provide further
insights to understand how reproductive factors may in-
fluence the general long-term health of women.
Most [4–7], but not all [8], relevant studies reported
that an earlier age at menarche was associated with a
higher risk for all-cause mortality and/or selected cause-
specific mortalities. Previous studies have reported no
association [8–10], or an inverse association [11, 12], for
ever versus never use of OCs with risk of all-cause
mortality and/or mortality from cancer or cardiovascular
disease. The association between parity and risk of all-
cause and cause-specific mortality is uncertain due to in-
consistent results across studies possibly because many
[13–18], but not all [19–21], had incomplete information
on other chronic disease risk factors which may con-
found the relationships, such as body mass index (BMI)
and smoking habits. Although fewer studies have exam-
ined breastfeeding and mortality risk, recent analyses
highlighted a lower risk of ischaemic heart disease [8] or
circulatory/cardiovascular disease mortality [22, 23] among
parous women who had ever versus never breastfed.
Finally, some investigations reported that an early age at
menopause was associated with a higher risk of mortality
particularly from cardiovascular outcomes [24–27].
As reproductive factors are intricately linked, we evalu-
ated several characteristics in relation to risk of all-cause
and cause-specific mortality while adjusting for potential
confounding factors, including BMI, physical activity,
smoking, and education level. This study provides evi-
dence from a large European prospective study on how
common reproductive factors may influence the long-
term health of women.
Methods
Study population
The European Prospective Investigation into Cancer
and Nutrition (EPIC) study includes 518,408 partici-
pants (366,040 women) aged 25–70 years at enrolment
(1992–2000). The cohort and data collection have been
previously described [28, 29]. Briefly, study participants
were recruited from the general population if they re-
sided in a particular town or province in 23 centres in
10 European countries (Denmark, France, Germany,
Greece, Italy, the Netherlands, Norway, Spain, Sweden,
and the United Kingdom). Exceptions to this were the
French cohort, which includes female members of the
health insurance for teachers; components of the Italian
(Ragusa and Turin) and Spanish cohorts that included
members of local blood donor associations; Utrecht
(the Netherlands) and Florence (Italy) cohorts, from
where women attending population-based mammo-
graphic screening programs were recruited; Oxford
(United Kingdom), where half of the cohort included
“health conscious” participants from England, Wales,
Scotland, and Northern Ireland who did not eat meat; and
the cohorts of France, Norway, Utrecht (the Netherlands),
and Naples (Italy) which included women only. Data on
diet, lifestyle characteristics, and medical history were
collected using baseline questionnaire and interview data.
Informed consent was provided by all participants and
ethical approval was obtained from the internal review
board of the International Agency for Research on Cancer
and from local ethics committees in the participating
countries. The full list of all local ethics committees is pro-
vided in Additional file 1.
Exclusions at the study baseline were men; participants
reporting prevalent diseases that could influence import-
ant confounders, diabetes (n = 8,298), myocardial infarc-
tion/heart attack (n = 2,063), angina (n = 3,275), stroke
(n = 1,920), or cancer (except non-melanoma skin can-
cer; n = 18,649); participants who were missing a lifestyle
questionnaire (n = 536), vital status (n = 743), or their
date of death (n = 216); those who reported having never
menstruated (n = 37) or were missing all of the follow-
ing: age at menarche or menopause (postmenopausal
women only), number of full term pregnancies (FTPs),
age at first and last FTP, OC use, and duration of breast-
feeding (n = 7,331). Finally, 322,972 women were in-
cluded in the analysis.
Exposure and covariate assessment
Reproductive characteristics assessed at the study base-
line included parity (live/still births only), number of
FTPs, age at first FTP, breastfeeding, infertility, OC ever
use and current use, duration of OC use up until the time
of recruitment, age at menarche, age at natural meno-
pause, total ovulatory years, and history of oophorectomy
or hysterectomy. Information on breastfeeding was only
available for the first three and the last FTP, therefore the
breastfeeding duration was calculated as the sum of these
pregnancies and for women reporting >4 FTPs as the
number of pregnancies multiplied by the mean duration
of breastfeeding per child. Women with infertility were
defined as those who had ever seen a doctor for fertility
problems or if they reported a diagnosis, treatment, or
surgery for fertility problems. OC formulations have
changed over time; most notably, current OCs have
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lower estrogen doses and may contain as little as 20 μg
ethinyl estradiol, while OCs that were prescribed before
1970 were typically high dose preparations (~100 μg
ethinyl estradiol) [30]. Data on OC formulation were
not available in the EPIC study; therefore, we carried
out sensitivity analyses of OC use after stratifying by
calendar year of first use, before 1970 (high dose),
1970–79 (medium dose), and 1980 and later (low dose).
The age at natural menopause was defined as the age at
the last menstrual period and participants who reported
a surgical menopause (due to hysterectomy or oophor-
ectomy) that occurred before reaching their age at nat-
ural menopause or participants missing the date of
their surgical menopause were excluded from this ana-
lysis. Age at menopause was categorized consistently
with previous EPIC study reports [31, 32] and the lar-
gest category (46–50 years) was set as the referent
group. Ovulatory years were calculated as the differ-
ence between a participant’s age at menopause (post-
menopausal) or their age at recruitment
(premenopausal or perimenopausal/unknown meno-
pause), and their age at menarche, minus the length of
time that a woman was pregnant or using OCs. An-
thropometric data [33], physical activity incorporating
occupational and recreational activities [34], smoking
status/intensity and duration, marital status, and edu-
cation level at the study baseline also were assessed.
Documentation of mortality endpoints
Follow-up of study subjects for vital status, cause, and
date of death commenced in the mid-1990s and the
current study uses the most recent data from the follow-
up cycle completed in 2010. Vital status data were col-
lected using record linkages with cancer registries, boards
of health, and death indices in Denmark, Italy (except
Naples), the Netherlands, Norway, Spain, Sweden, and the
United Kingdom or through active follow-up (inquiries by
mail or telephone to participants, municipal registries,
regional health departments, physicians, and hospitals) in
Germany, Greece, Naples, Italy, and France following
standardized guidelines for the collection of endpoint data
in the EPIC Study (IARC, 1998, unpublished). Procedures
to ensure that valid and complete active follow-up data
were collected were previously described for the German
[35], Greek [36], Naples [37], and French [38] subcohorts.
Causes of death were coded according to the 10th revision
of the International Statistical Classification of Diseases,
Injuries, and Causes of Death. For cause-specific mortality
analyses, deaths were grouped into categories representing
the most common causes of death (cancer, circulatory
disease), and categories were further subdivided into the
most commonly occurring disease subgroups; breast can-
cer, cerebrovascular, and ischaemic heart disease.
Statistical analyses
Cox proportional hazards regression modelling using
age as the underlying time metric with the subjects’ age
at recruitment as the entry time and their age at death
or censoring, emigration, or last complete follow-up,
whichever occurred first, as the exit time, were used to
estimate hazard ratios (HRs) and 95 % confidence inter-
vals (CIs) for the associations between reproductive
characteristics and mortality risk. To account for differ-
ences across study centres in the timing to report
causes of death, in cause-specific analyses the follow-up
dates were truncated to when 80 % of the causes of
death at each centre were known; specifically, June
2005 (Cambridge), December 2006 (France, Varese, Turin,
Naples, Granada, Murcia, Malmo, Denmark), December
2007 (Florence, San Sebastian, Umeå, Norway), December
2008 (Ragusa, Asturias, Navarra, the Netherlands), and
June 2009 (Oxford). For Germany and Greece, the end of
the follow-up was the last known date of contact or death;
this extended to July 2010 (Germany) and December 2009
for Greece.
Multivariate analyses were adjusted for important con-
founders that were selected a priori; menopausal status,
BMI, physical activity, education level, and smoking sta-
tus/intensity and duration while including an indicator
category for missing data, and all models were stratified
by the study centre and the participant’s age at recruit-
ment. Sensitivity analyses that excluded individuals with
missing values for these covariates showed similar re-
sults; these data are not presented here. We examined
alcohol intake as a potential confounder by classifying
individuals into quartiles based on their levels of ethanol
intake in grams per day but did not include this in the
final models because the HRs were not altered by >10 %
[39]. Continuous variables were modelled to calculate a
P for trend.
We carried out further separate analyses of all-cause
mortality risk to examine the following associations: parity
(parous versus nulliparous) when stratifying by marital
status (never, ever married); number of FTPs when strati-
fying by BMI (<25 kg/m2, ≥25), since having more chil-
dren may lead to weight gain; age at menarche after
stratifying by BMI because an early age at menarche has
been linked to a higher BMI in adulthood; breastfeeding
duration after stratifying by the number of FTPs (1–2
FTPs, >2); and age at menopause and ever use of OCs
were assessed separately after stratifying by smoking sta-
tus. In each of these models, a P for statistical interaction
was calculated using a likelihood ratio test to compare
multivariate models with and without multiplicative
interaction terms. Additional sensitivity analyses were
conducted after restricting to women who were post-
menopausal at recruitment, or without excluding par-
ticipants who reported prevalent conditions. In analyses
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of age at menopause, we conducted further sensitivity ana-
lysis of breast cancer mortality without excluding women
who had a surgically-induced menopause. The proportional
hazards assumption was verified using the Grambsch and
Therneau [40] method. A two tailed P <0.05 was consid-
ered statistically significant. Analyses were performed using
the survival package [41] in R (version 3.0.2) [42].
Results
Baseline characteristics
After a mean follow-up of 12.9 (SD = 2.3) years, 14,383
all-cause deaths were identified, including 5,938 cancer
deaths and 2,404 deaths from circulatory diseases. The
distribution of most reproductive characteristics was
similar across countries (Table 1) although there were
differences in the proportion of women who used OCs
(11–40 % in Greece, Spain, and Italy versus ≥58 % in
other countries). We also observed a slightly lower pro-
portion of parous women in the Netherlands and the
United Kingdom. In the French cohort, fewer parous
women had ever breastfed (72 % versus ≥81 % in other
countries).
Association of reproductive factors with all-cause
mortality
Parity was associated with a lower risk of all-cause mor-
tality (parous versus nulliparous; HR = 0.80; CI, 0.76–
0.84; Table 2). Having an early or late age at first FTP
versus having a first FTP at age 26–30 was associated
with a higher risk for all-cause mortality (first FTP ≤20:
HR = 1.10; CI, 1.04–1.17; first FTP ≥31: HR = 1.08; CI,
1.01–1.16). Among parous women, ever versus never
breastfeeding was inversely associated with risk of all-
cause mortality (HR = 0.92; CI, 0.87–0.97). In contrast,
there was no association with the number of FTPs or
breastfeeding duration (P for trend ≥0.79).
Having a late versus early age at menarche was associ-
ated with a lower risk of all-cause mortality; women who
underwent menarche at age ≥15 years compared with
age <12 had a 10 % reduction in risk of death (HR =
0.90; CI, 0.85–0.96) and there was an inverse trend
across age at menarche categories (P for trend = 0.038).
Having an early age at natural menopause was associated
with a higher risk of all-cause mortality (≤45 years ver-
sus 46–50; HR = 1.09; CI, 1.01–1.17), while overall there
was a suggestion of lower risk with a later age at meno-
pause (P for trend <0.001). There was no association be-
tween infertility, total ovulatory years, oophorectomy, or
hysterectomy with risk of all-cause mortality.
In stratified analyses, an inverse association between
ever versus never use of OCs and risk of all-cause mortal-
ity was observed only in never/former smokers (HR =
0.90; CI, 0.86–0.95; n = 3,736 deaths were observed among
ever users of OCs), but not current smokers (OC ever
versus never use; HR = 0.98; CI, 0.91–1.05; n = 2,076
deaths occurred in ever users of OCs, P for interaction =
0.0021); analyses of OCs and mortality risk were therefore
restricted to participants who were never/former smokers.
There was a similar lower risk of all-cause mortality in
former users and current users of OCs at the study
baseline, although the finding for current users was
non-significant possibly due to the small number of
deaths (n = 140) in this category. The lowered risk of
all-cause mortality associated with ever use of OCs was
observed across all categories grouped by calendar year
of first use (before 1970: HR = 0.89; CI, 0.84–0.95;
1970s: HR = 0.89; CI, 0.83–0.95; 1980s and later: HR =
0.84; CI, 0.71–0.99; data not shown). In contrast, there
was no association with the duration of OC use among
ever users of OCs irrespective of smoking status (P for
interaction = 0.283 for never/former and current smokers).
The inverse association between having a late age at
menarche (age ≥15 years versus <12) and risk of all-
cause mortality was only observed in women with a
BMI ≥25 kg/m2 (HR = 0.82; CI, 0.75–0.89; P for trend =
0.0034). In contrast, there was no association for partic-
ipants with a BMI <25 kg/m2 (HR = 0.98; CI, 0.90–1.07;
P for trend = 0.58; P for interaction = 0.016). Results
from the stratified analyses are detailed in Additional file 2.
The higher incidence of all-cause mortality among women
with an early age at menopause (menopause age ≤45 years
versus 46–50) was restricted to former and current
smokers (HR = 1.22; CI, 1.10–1.35; P for trend <0.001),
while there was no association in never smokers (HR =
1.02; CI, 0.91–1.13; P for trend = 0.35; P for interaction =
0.012). There was no difference in the risk associations for
all-cause mortality in analyses of parity when stratifying by
marital status, for the number of FTPs according to BMI,
or with breastfeeding duration by the number of FTPs (P
for interaction ≥0.34). In sensitivity analyses, we ob-
served similar results for all-cause mortality analyses
when restricting analyses to postmenopausal women
only, or when participants who reported prevalent con-
ditions (diabetes, heart conditions, or cancer) were not
excluded (data not shown). In sensitivity analyses of age
at menopause without excluding women who reported a
surgically-induced menopause in relation to breast cancer
mortality, we observed similar results to those reported
for age at natural menopause (data not shown).
Cancer mortality
Risk of total cancer mortality was lower in parous versus
nulliparous women (HR = 0.87; CI, 0.80–0.93) and with
a later age at menarche (age ≥15 years versus <12; HR =
0.89; CI, 0.81–0.98; P for trend = 0.042; Table 3). Among
parous women, having two or three FTPs versus one
was associated with a lower risk of total cancer mortality
(e.g. 3 FTPs versus 1; HR = 0.89; CI, 0.81–0.97), but
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Table 1 Age standardizeda reproductive and lifestyle characteristics of the EPIC study population by country
Total Denmark France Germany Greece Italy Norway Spain Sweden The Netherlands United Kingdom
No. of participants 322,972 27,887 66,878 26,766 13,893 30,008 35,215 23,828 19,930 26,223 52,344
Number of deaths 14,383 1,879 2,913 671 527 834 756 625 1,583 1,419 3,176
Mean (SD)
Age at recruitment, years 50.3 (9.6) 56.2 (4.4) 52.1 (6.6) 48.1 (8.9) 51.6 (12.3) 50.0 (8.0) 47.6 (4.3) 47.5 (8.3) 54.9 (8.1) 50.2 (11.6) 47.1 (14.1)
Duration OC use, yearsb,c 7.7 (7.3) 9.4 (6.4) 7.4 (6.3) 12.4 (8.5) 2.5 (2.8) 4.1 (4.8) 5.0 (4.5) 3.7 (3.6) 9.7 (8.3) 9.9 (7.3) 7.6 (6.8)
Number of FTPsc,d,e 2.3 (1.0) 2.2 (0.6) 2.3 (0.9) 2.0 (0.9) 2.3 (1.0) 2.1 (0.9) 2.4 (0.8) 2.8 (1.3) 2.2 (0.9) 2.6 (1.2) 2.3 (1.0)
Age at first FTPc,d 24.9 (4.4) 23.8 (3.1) 24.9 (3.7) 24.2 (4.4) 24.1 (4.7) 25.8 (4.3) 24.0 (3.7) 24.9 (3.8) 24.6 (4.1) 25.4 (4.3) 25.6 (4.9)
Breastfeeding, monthsc,f 9.6 (10.6) 9.4 (6.3) 5.5 (5.2) 5.4 (6.4) 13.7 (16.3) 9.1 (8.5) 13.6 (9.5) 13.1 (12.8) 9.7 (7.3) 6.6 (6.9) 9.9 (12.9)
Age at menarche, yearsc 13.1 (1.5) 13.7 (1.2) 12.9 (1.3) 13.2 (1.5) 13.2 (1.6) 12.6 (1.5) 13.3 (1.1) 13.0 (1.6) 13.3 (1.5) 13.3 (1.6) 12.9 (1.6)
Age at menopause, yearsc,g 49.4 (4.4) 49.9 (3.9) 50.2 (4.3) 50.1 (3.2) 48.0 (4.7) 49.2 (4.1) 48.6 (3.3) 48.8 (4.4) – 49.1 (4.5) 49.2 (4.6)
BMI, kg/m2 24.9 (4.4) 25.5 (3.2) 23.0 (3.2) 25.7 (4.6) 28.5 (5.2) 25.6 (4.3) 24.5 (3.1) 28.5 (4.6) 24.7 (4.2) 25.1 (4.2) 24.6 (4.2)
Percentages
Ever use OCsc 59 58 60 80 11 40 60 36 61 76 68
Parousc 85 88 90 86 90 87 92 89 86 81 78
Ever breastfedc,e 85 93 72 84 88 84 94 89 95 81 83
Infertilityc,h 5 – 6 1 4 6 – 4 – 3 5
Premenopausal 35 7 27 37 38 38 23 42 27 37 38
Postmenopausal 43 73 45 42 45 43 44 41 48 40 43
Surgical menopausei 3 5 3 3 6 4 0 6 0 2 4
Perimenopausal/unknown menopause 19 16 25 17 12 15 32 11 26 20 15
Hysterectomyc,j 11 14 10 16 9 9 5 10 – 16 16
Oophorectomyc,j 7 10 6 8 8 8 1 9 – 8 8
Current smokerc,k 20 31 9 18 19 26 32 15 25 29 11
Marital status: single 9 0 17 8 4 6 0 0 7 12 9
Ever marriedl 72 0 80 92 96 93 81 0 92 87 90
Marital status: unknown 19 100 4 0 0 1 19 100 0 0 0
BMI, Body mass index; FTP, Full term pregnancy; OCs, Oral contraceptives
aAll variables (with the exception of age) were age standardized using 5-year age groups to the age distribution of the entire study population
bAmong ever users of OCs
cVariables had missing data (≤4.2 % missing) with the exception of ever breastfed among parous (6.1 % missing), duration OC use in ever users (9.5 % missing), and age at natural menopause (26.3 % missing)
dFTPs includes live births and stillbirths
eAmong parous women
fAmong women with a FTP who had ever breastfed
gPostmenopausal women only; exclusions were participants from Sweden (no data for hysterectomy/oophorectomy), those who reported a surgical menopause (hysterectomy/oophorectomy), or if information on
surgical menopause was not available
hDenmark, Sweden, Norway and the Bilthoven study centre were excluded since data were not available
iDefined as bilateral oophorectomy only
jSweden was excluded from these comparisons because data were not available
kCurrent smoking included smoking of cigarettes, pipes, or cigars
lEver married includes living together, divorced, separated, and widowed
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Table 2 Association of reproductive characteristics with all-cause mortality in the EPIC study
Variable Value Cases / non-cases Model 1 HRa (95 % CI) Model 2 HRb (95 % CI)
Parous No 2,220 / 45,746 1.00 (reference) 1.00 (reference)
Yes 11,757 / 254,871 0.80 (0.76–0.83) 0.80 (0.76–0.84)
Number of FTPsc 1 2,307 / 45,881 1.00 (reference) 1.00 (reference)
2 5,026 / 122,430 0.87 (0.83–0.91) 0.91 (0.86–0.96)
3 2,529 / 56,316 0.83 (0.79–0.88) 0.87 (0.82–0.92)
4 1,047 / 16,278 0.97 (0.90–1.04) 0.98 (0.91–1.06)
5 350 / 4,448 0.97 (0.87–1.09) 0.97 (0.86–1.09)
≥6 237 / 2,290 1.09 (0.95–1.25) 1.08 (0.94–1.24)
P for trendd 0.91 0.79
Age at first FTP, yearsc ≤20 1,812 / 37,390 1.30 (1.23–1.38) 1.10 (1.04–1.17)
21–23 3,121 / 68,203 1.13 (1.07–1.19) 1.05 (1.00–1.11)
24–25 2,173 / 49,889 1.02 (0.97–1.08) 1.00 (0.95–1.06)
26–30 3,287 / 72,649 1.00 (reference) 1.00 (reference)
≥31 1,281 / 25,749 1.08 (1.01–1.15) 1.08 (1.01–1.16)
Breastfeedingc Never 1,721 / 36,691 1.00 (reference) 1.00 (reference)
Ever 9,148 / 202,910 0.88 (0.83–0.93) 0.92 (0.87–0.97)
Breastfeeding, monthse ≤1 949 / 20,021 1.00 (reference) 1.00 (reference)
>1 to ≤3 1,753 / 39,935 1.01 (0.93–1.09) 1.01 (0.93–1.09)
>3 to ≤6 1,846 / 41,685 0.94 (0.87–1.02) 0.97 (0.89–1.05)
>6 to ≤12 2,224 / 47,802 0.90 (0.83–0.98) 0.95 (0.88–1.03)
>12 to ≤18 986 / 23,319 0.81 (0.74–0.89) 0.88 (0.80–0.97)
>18 1,276 / 27,949 0.88 (0.80–0.96) 0.97 (0.89–1.07)
P for trendd 0.013 0.85
Infertilityf No 8,958 / 199,770 1.00 (reference) 1.00 (reference)
Yes 360 / 9,869 1.06 (0.95–1.18) 1.06 (0.95–1.18)
OC use in never or former Never 6,379 / 100,292 1.00 (reference) 1.00 (reference)
smokers at baselineg Ever 3,736 / 140,642 0.90 (0.85–0.94) 0.90 (0.86–0.95)
Formerh 3,475 / 122,414 0.89 (0.85–0.94) 0.90 (0.86–0.95)
Currenth 140 / 12,959 0.89 (0.74–1.07) 0.92 (0.76–1.11)
Duration OC use, yearsg,i ≤1 679 / 25,490 1.00 (reference) 1.00 (reference)
>1 to <5 721 / 30,600 0.99 (0.89–1.10) 0.99 (0.89–1.11)
5 to <10 705 / 30,859 0.95 (0.85–1.06) 0.96 (0.86–1.07)
10 to <15 616 / 21,267 1.05 (0.94–1.18) 1.06 (0.94–1.18)
≥15 526 / 18,583 1.02 (0.90–1.15) 1.02 (0.91–1.16)
P for trendd 0.36 0.32
Age at menarche, years <12 1,977 / 45,763 1.00 (reference) 1.00 (reference)
12 2,714 / 65,654 0.92 (0.86–0.97) 0.95 (0.89–1.01)
13 3,378 / 79,701 0.88 (0.84–0.94) 0.92 (0.87–0.98)
14 3,224 / 66,159 0.89 (0.84–0.95) 0.93 (0.88–0.98)
≥15 2,774 / 47,743 0.88 (0.82–0.93) 0.90 (0.85–0.96)
P for trendd 0.004 0.038
Age at natural menopause, yearsj ≤45 1,080 / 12,399 1.15 (1.07–1.24) 1.09 (1.01–1.17)
46–50 2,427 / 32,488 1.00 (reference) 1.00 (reference)
51–52 1,064 / 14,537 0.88 (0.82–0.95) 0.91 (0.85–0.99)
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having more than three FTPs versus one was not associ-
ated with risk. Among never/former smokers, we ob-
served a lower risk of total cancer mortality in ever
versus never users of OCs (HR = 0.91; CI, 0.85–0.98),
while there was no association with OC use in partici-
pants who were current smokers at baseline (ever versus
never users of OCs; HR = 1.00; CI, 0.90–1.12). In ana-
lyses of breast cancer mortality, there was a strong de-
creased risk in parous versus nulliparous women (HR =
0.70; CI, 0.58–0.85) and a trend of lower mortality risk
with a higher number of FTPs (P for trend = 0.012). There
was no association with other reproductive characteristics
although the number of breast cancer deaths (n = 749)
was limited.
Circulatory disease mortality
Reproductive characteristics that were inversely associ-
ated with risk of death from circulatory disease in-
cluded parity (parous versus nulliparous; HR = 0.86; CI,
0.76–0.96), breastfeeding (ever versus never breastfed;
HR = 0.80; CI, 0.70–0.91), and a late age at menarche
(≥15 years versus <12; HR = 0.83; CI, 0.72–0.96; Table 4).
Never/former smokers at baseline who had ever versus
never used OCs had a lower risk of circulatory disease
death (HR = 0.85; CI, 0.75–0.97). In contrast, among
current smokers at baseline, there was no association with
ever use of OCs (HR = 0.98; CI, 0.81–1.17). There was a
small but non-significant increase in risk of circulatory
disease death for current OC users as compared with
never users of OCs at baseline (HR = 1.48; CI, 0.90–2.43;
based on n = 22 deaths). In sub-analyses of ischaemic
heart disease mortality, we observed strong inverse associ-
ations with parity (parous versus nulliparous women),
breastfeeding (ever versus never breastfed), and a sug-
gestive inverse association with a late versus early age
at natural menopause. In analyses of death from cere-
brovascular disease, there were non-significant inverse
associations with a late versus early age at menarche,
and in ever versus never users of OCs (former/never
smokers only). In contrast, non-smoking participants
who reported current OC use at the study baseline
had a higher risk of cerebrovascular disease death
Table 2 Association of reproductive characteristics with all-cause mortality in the EPIC study (Continued)
53–55 1,003 / 12,753 0.86 (0.80–0.93) 0.92 (0.85–0.99)
>55 339 / 3,287 0.90 (0.80–1.01) 0.95 (0.85–1.07)
P for trendd <0.001 <0.001
Total ovulatory lifespan, yearsk,l 0–22 1,180 / 56,387 1.00 (reference) 1.00 (reference)
22–29 1,621 / 53,629 0.96 (0.89–1.05) 0.99 (0.91–1.07)
29–34 2,148 / 52,270 0.92 (0.84–0.99) 0.96 (0.89–1.04)
≥34 3,115 / 51,923 0.89 (0.82–0.97) 0.98 (0.91–1.06)
P for trendd 0.004 0.86
Oophorectomyl No 11,167 / 266,535 1.00 (reference) 1.00 (reference)
Yes 1,202 / 18,603 1.05 (0.98–1.11) 1.01 (0.93–1.10)
Hysterectomyl No 10,606 / 257,298 1.00 (reference) 1.00 (reference)
Yes 1,972 / 30,608 1.01 (0.96–1.06) 1.00 (0.94–1.05)
FTP, Full term pregnancy; OCs, Oral contraceptives
aCox regression stratified by age (continuous) and study centre
bCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical
postmenopausal [bilateral oophorectomy]), body mass index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m2), physical activity index (inactive [Ref], moderately
inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/professional school, secondary school/longer education
including university, or unknown), smoking status/intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/day,
former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking
duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40, 40+ years, unknown), and stratified by age and study centre
cRestricted to parous women. A FTP was defined as live births and stillbirths
dP for trend values are based on continuous variables: the number of FTPs was modelled as 1 to ≥10; age at menarche as ≤8, 9–19, ≥20; age at menopause as
<35, 35–60, >60
eAmong parous women who had ever breastfed (sum of all FTPs)
fDenmark, Sweden, Norway, and the Bilthoven (Netherlands) study centre were excluded since data were not available
gRestricted to participants who were never or former smokers, therefore models were adjusted for the same factorsb and a modified smoking status/intensity
variable (never [Ref], former quit ≤10 years, former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)
hDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use
i Among ever users of OCs
jAmong postmenopausal women; excluded participants from Sweden (no data for hysterectomy/oophorectomy), those who reported a surgical menopause
(hysterectomy and/or unilateral/bilateral oophorectomy), or if information on surgical menopause was missing
kThe total ovulatory lifespan is the difference between the age at natural menopause and the age at menarche for postmenopausal women, or the difference
between the age at recruitment and the age at menarche for premenopausal/perimenopausal/unknown menopausal status women, minus the amount of time
that a woman was pregnant (number of full term pregnancies × nine months) and/or used OCs
lSweden was excluded from these comparisons (no data for hysterectomy/oophorectomy), therefore age at natural menopause could not be determined
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Table 3 Association of reproductive characteristics with total cancer and breast cancer mortality in the EPIC study
Total cancer (n = 5,938) Breast cancer (n = 749)
ICD-10 code C00–D48 C50
Variable Value Cases/ non-cases HRa (95 % CI) Cases / non-cases HRa (95 % CI)
Parous Yes 4,973 / 261,634 0.87 (0.80–0.93) 598 / 266,009 0.70 (0.58–0.85)
Number of FTPsb,c 1 944 / 47,240 1.00 (reference) 135 / 48,049 1.00 (reference)
2 2,164 / 125,284 0.91 (0.84–0.98) 268 / 127,180 0.74 (0.60–0.92)
3 1,069 / 57,773 0.89 (0.81–0.97) 119 / 58,723 0.70 (0.54–0.90)
4 442 / 16,880 1.05 (0.93–1.18) 55 / 24,591 0.68 (0.49–0.95)
5 118 / 4,680 0.86 (0.71–1.05)
≥6 88 / 2,438 1.11 (0.89–1.39)
P for trendd 0.85 0.012
Age at first FTP, yearsb ≤20 781 / 38,420 1.03 (0.94–1.14) 90 / 39,111 0.89 (0.68–1.16)
21–23 1,267 / 70,055 0.97 (0.90–1.05) 135 / 71,187 0.79 (0.63–0.99)
24–25 915 / 51,141 0.95 (0.87–1.03) 114 / 51,942 0.91 (0.72–1.15)
26–30 1446 / 74,481 1.00 (reference) 187 / 75,740 1.00 (reference)
≥31 531 / 26,496 1.06 (0.96–1.17) 70 / 26,957 1.05 (0.79–1.39)
Breastfeedinge Ever 3,964 / 208,077 0.99 (0.91–1.08) 484 / 211,557 1.01 (0.79–1.29)
Breastfeeding, monthsf ≤1 399 / 20,571 1.00 (reference) 58 / 20,912 1.00 (reference)
>1 to ≤3 768 / 40,917 0.96 (0.85–1.09) 102 / 41,583 0.87 (0.62–1.21)
>3 to ≤6 783 / 42,744 0.92 (0.81–1.04) 82 / 43,445 0.68 (0.48–0.96)
>6 to ≤12 965 / 49,056 0.93 (0.83–1.05) 101 / 49,920 0.69 (0.49–0.97)
>12 to ≤18 434 / 23,868 0.87 (0.76–1.00) 63 / 24,239 0.88 (0.60–1.27)
>18 579 / 28,644 1.04 (0.90–1.19) 74 / 29,149 0.94 (0.65–1.37)
P for trendd 0.23 0.35
OC use in never or former Never 2,376 / 104,288 1.00 (reference) 257 / 106,407 1.00 (reference)
smokers at baselineg Ever 1,775 / 142,587 0.91 (0.85–0.98) 313 / 144,049 1.11 (0.91–1.35)
Formerh 1,656 / 124,219 0.91 (0.85–0.98) 291 / 125,584 1.12 (0.92–1.36)
Currenth 78 / 13,019 0.93 (0.73–1.20) 18 / 13,079 0.87 (0.50–1.50)
Duration of OC use, yearsg,i ≤1 325 / 25,843 1.00 (reference) 53 / 26,115 1.00 (reference)
>1 to <5 340 / 30,979 0.96 (0.82–1.12) 64 / 31,255 1.00 (0.69–1.45)
5 to <10 372 / 31,188 1.06 (0.91–1.23) 59 / 31,501 0.94 (0.64–1.37)
10 to <15 305 / 21,576 1.09 (0.92–1.28) 63 / 21,818 1.33 (0.91–1.94)
≥15 277 / 18,825 1.07 (0.90–1.27) 53 / 19,049 1.22 (0.81–1.83)
P for trendd 0.195 0.106
Age at menarche, years <12 811 / 46,926 1.00 (reference) 98 / 47,639 1.00 (reference)
12 1,147 / 67,220 0.97 (0.89–1.06) 162 / 68,205 1.17 (0.91–1.51)
13 1,380 / 81,686 0.91 (0.83–0.99) 164 / 82,902 0.93 (0.72–1.20)
14 1,365 / 68,009 0.95 (0.87–1.04) 198 / 69,176 1.27 (0.99–1.63)
≥15 1,125 / 49,388 0.89 (0.81–0.98) 114 / 50,399 0.89 (0.67–1.18)
P for trendd 0.042 0.35
Age at natural menopause, yearsj ≤45 371 / 13,105 0.97 (0.86–1.10) 30 / 13,446 0.68 (0.45–1.03)
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(HR = 2.62; CI, 1.30–5.26), but this finding was based
on a small number (n = 13) of deaths; there were too
few current OC users who were also current smokers
at the study baseline to evaluate this subgroup.
Discussion
In a large and comprehensive prospective study repre-
senting data from 10 European countries, we observed
that, after controlling for factors known to influence
mortality risk (such as BMI, smoking habits and physical
activity), childbirth, breastfeeding among parous women,
ever use of OCs among non-smokers, a later age at
menopause, and a later age at menarche were associated
with a significantly lower risk of all-cause mortality.
Most of these associations were also apparent when we
considered cause-specific deaths from total cancer and
ischaemic heart disease. Importantly, these reproductive
factors are common exposures and with a better under-
standing of how these factors may influence long-term
health this information may assist in the development of
new clinical strategies for the improvement of women’s
health.
The inverse association for parous as compared with
nulliparous women with risk of all-cause, total cancer,
breast cancer, and ischaemic heart disease mortality is
consistent with previous studies [13–17, 43, 44]. It is
possible that other underlying factors may explain the
association between parous versus nulliparous women;
for example, some women may be nulliparous because
they were chronically unwell. However, our data did not
suggest that nulliparous women had poorer health as
their BMI, physical activity levels, and smoking status
were similar to parous women. Notable differences were
that a higher proportion of nulliparous women had ob-
tained a higher education level and fewer nulliparous
women had ever married. Among parous women, we
observed a trend of lower risk for breast cancer mortal-
ity with an increasing number of FTPs. In contrast, the
number of FTPs was not associated with other mortality
outcomes. It has been suggested that having ≥4 births
may increase a mother’s risk of circulatory disease mor-
tality [21], possibly by inducing hypertensive changes
[45] and/or by increasing their body weight [46]. How-
ever, in a study of highly parous women in Northern
Finland, only women with ≥10 births (versus 2–4) had a
higher risk of mortality from haemorrhagic stroke [20].
Consistent with previous studies [8, 23], we observed
that parous women who had ever breastfed had a lower
risk of mortality from all-causes and ischaemic heart
disease. Prior studies have observed that women who
never breastfed [47] and/or had a shorter lactation
period [22, 48] had a higher risk to develop hyperten-
sion. Similar to prior reports [4–6, 8], we observed that
a later age at menarche was associated with a lower
risk of all-cause, total cancer, and circulatory mortality.
Having an earlier age at menarche has been associated
with elevated blood pressure and glucose intolerance
[49], increased body fat in early adulthood [50], or
obesity in adulthood [51], all of which could explain
the possible link between the age at menarche and risk
of mortality outcomes later in life. We also observed
that an early age at menopause was associated with a
higher risk of all-cause mortality, but this association was
attenuated and non-significant in never smokers, which
Table 3 Association of reproductive characteristics with total cancer and breast cancer mortality in the EPIC study (Continued)
46–50 988 / 33,921 1.00 (reference) 120 / 34,789 1.00 (reference)
51–52 448 / 15,151 0.98 (0.88–1.10) 43 / 15,556 0.80 (0.56–1.14)
53–55 448 / 13,307 1.08 (0.96–1.21) 53 / 13,702 1.03 (0.73–1.45)
>55 141 / 3,483 1.12 (0.93–1.34) 13 / 3,611 0.87 (0.47–1.61)
P for trendd 0.080 0.37
FTP, Full term pregnancy; OCs, Oral contraceptives; ICD-10, International Statistical Classification of Diseases Injuries and Causes of Death (10th revision)
aCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical
postmenopausal (bilateral oophorectomy)), body mass index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m2), physical activity index (inactive [Ref], moderately
inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/professional school, secondary school/longer education
including university, or unknown), smoking status/intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/day,
former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking
duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40, 40+ years, unknown), and stratified by age (continuous) and study centre
bFTP includes live births and stillbirths
cFor breast cancer the top categories were combined as indicated due to small numbers
dP for trend values are based on continuous variables: the number of FTPs was modelled as 1 to ≥10; age at menarche as ≤8, 9–19, ≥20; age at menopause as
<35, 35–60, >60
eAmong parous women
fAmong parous women who had ever breastfed (sum of all FTPs)
gRestricted to participants who were never or former smokers, therefore models were adjusted for the same factorsa and a modified smoking status/intensity
variable (never [Ref], former quit ≤10 years, former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)
hDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use
iAmong ever users of OCs
jAmong postmenopausal women; exclusions included participants from Sweden (no data for hysterectomy/oophorectomy), those who had a surgical menopause
(hysterectomy and/or oophorectomy), or if information on surgical menopause was missing
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Table 4 Association of reproductive characteristics with mortality from circulatory diseases in the EPIC study
Circulatory disease (n = 2,404) Cerebrovascular disease (n = 808) Ischaemic heart disease (n = 732)
ICD-10 codes I00–I99 I60–I69 I20–I25
Variable Value Cases / non-cases HRa (95 % CI) Cases / non-cases HRa (95 % CI) Cases / non-cases HRa (95 % CI)
Parous Yes 1,970 / 264,637 0.86 (0.76–0.96) 655 / 265,952 0.93 (0.76–1.13) 598 / 266,009 0.79 (0.65-0.97)
Number of FTPsb 1 374 / 47,810 1.00 (reference) 114 / 48,070 1.00 (reference) 117 / 48,067 1.00 (reference)
2 799 / 126,649 0.92 (0.81–1.04) 281 / 127,167 1.06 (0.85–1.32) 240 / 127,208 0.91 (0.73-1.14)
3 431 / 58,411 0.88 (0.76–1.02) 135 / 58,707 0.90 (0.70–1.17) 139 / 58,703 0.93 (0.73-1.20)
4 198 / 17,124 0.95 (0.79–1.13) 66 / 17,256 1.03 (0.75–1.41) 48 / 17,274 0.74 (0.52-1.05)
5 63 / 4,735 0.85 (0.65–1.12) 21 / 4,777 0.92 (0.57–1.48) 18 / 4,780 0.78 (0.47-1.29)
≥6 62 / 2,464 1.13 (0.85–1.50) 23 / 2,503 1.49 (0.93–2.39) 19 / 2,507 1.12 (0.67-1.88)
P for trendc 0.85 0.42 0.29
Age at first FTP, yearsd ≤20 304 / 38,897 1.15 (0.99–1.34) 97 / 39,104 1.14 (0.86–1.50) 105 / 39,096 1.14 (0.86-1.51)
21–23 497 / 70,825 1.11 (0.98–1.26) 150 / 71,172 0.96 (0.76–1.23) 140 / 71,182 0.96 (0.74-1.24)
24–25 359 / 51,697 1.05 (0.92–1.20) 122 / 51,934 1.00 (reference) 106 / 51,950 1.00 (reference)
26–30 557 / 75,370 1.00 (reference) 199 / 75,728 0.97 (0.78–1.23) 166 / 75,761 0.99 (0.77-1.26)
≥31 237 / 26,790 1.06 (0.90–1.23) 79 / 26,948 0.90 (0.67–1.21) 74 / 26,953 1.10 (0.81-1.49)
Breastfeedingd Ever 1,534 / 210,507 0.80 (0.70–0.91) 526 / 211,515 0.94 (0.74–1.21) 445 / 211,596 0.69 (0.54-0.87)
Breastfeeding, monthse ≤1 135 / 20,835 1.00 (reference) 38 / 20,932 1.00 (reference) 41 / 20,929 1.00 (reference)
>1 to ≤3 282 / 41,403 1.16 (0.94–1.43) 101 / 41,584 1.47 (1.00–2.14) 86 / 41,599 1.22 (0.83-1.79)
>3 to ≤6 276 / 43,251 1.05 (0.85–1.30) 93 / 43,434 1.20 (0.82–1.77) 91 / 43,436 1.22 (0.83-1.79)
>6 to ≤12 359 / 49,662 1.02 (0.83–1.26) 115 / 49,906 1.10 (0.75–1.60) 102 / 49,919 0.99 (0.68-1.45)
>12 to ≤18 184 / 24,118 0.98 (0.78–1.23) 69 / 24,233 1.18 (0.78–1.77) 51 / 24,251 0.94 (0.61-1.44)
>18 287 / 28,936 1.04 (0.83–1.31) 110 / 29,113 1.28 (0.85–1.90) 71 / 29,152 0.92 (0.60-1.40)
P for trendc 0.48 0.076 0.153
OC use in never or former Never 1,274 / 105,390 1.00 (reference) 467 / 106,197 1.00 (reference) 352 / 106,312 1.00 (reference)
smokers at baselinef Ever 427 / 143,935 0.85 (0.75–0.97) 144 / 144,218 0.80 (0.64–1.01) 102 / 144,260 0.87 (0.67-1.12)
Formerg 397 / 125,478 0.84 (0.74–0.96) 129 / 125,746 0.78 (0.62–0.98) 100 / 125,775 0.87 (0.67-1.13)
Currentg,h 22 / 13,075 1.48 (0.90–2.43) 13 / 13,084 2.62 (1.30–5.26) 2 / 13,095 -
Duration of OC use, yearsf,i ≤1 72 / 26,096 1.00 (reference) 23 / 26,145 1.00 (reference) 21 / 26,147 1.00 (reference)
>1 to <5 72 / 31,247 0.95 (0.68–1.33) 23 / 31,296 0.95 (0.52–1.73) 21 / 31,298 0.97 (0.52-1.83)
5 to <10 80 / 31,480 0.98 (0.70–1.36) 34 / 31,526 1.40 (0.80–2.44) 14 / 31,546 0.58 (0.29-1.16)
10 to <15 84 / 21,797 1.22 (0.88–1.70) 22 / 21,859 1.08 (0.59–2.00) 22 / 21,859 1.09 (0.58-2.05)
≥15 70 / 19,032 1.14 (0.80–1.62) 30 / 19,072 1.63 (0.91–2.94) 15 / 19,087 0.96 (0.48-1.94)
P for trendc 0.38 0.177 0.91
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Table 4 Association of reproductive characteristics with mortality from circulatory diseases in the EPIC study (Continued)
Age at menarche, years <12 325 / 47,412 1.00 (reference) 105 / 47,632 1.00 (reference) 107 / 47,630 1.00 (reference)
12 411 / 67,956 0.84 (0.73–0.98) 132 / 68,235 0.80 (0.62–1.04) 123 / 68,244 0.80 (0.62-1.04)
13 555 / 82,511 0.89 (0.77–1.02) 186 / 82,880 0.86 (0.67–1.09) 165 / 82,901 0.81 (0.63-1.03)
14 559 / 68,815 0.91 (0.79–1.05) 189 / 69,185 0.88 (0.69–1.12) 164 / 69,210 0.80 (0.62-1.02)
≥15 494 / 50,019 0.83 (0.72–0.96) 165 / 50,348 0.79 (0.61–1.02) 160 / 50,353 0.80 (0.62-1.03)
P for trendc 0.47 0.51 0.30
Age at natural menopause, yearsj ≤45 251 / 13,225 1.07 (0.91–1.25) 78 / 13,398 1.00 (0.75–1.32) 85 / 13,391 1.14 (0.86-1.50)
46–50 499 / 34,410 1.00 (reference) 163 / 34,746 1.00 (reference) 157 / 34,752 1.00 (reference)
51–52 189 / 15,410 0.79 (0.67–0.94) 68 / 15,531 0.83 (0.62–1.12) 43 / 15,556 0.58 (0.41-0.82)
53–55 166 / 13,589 0.75 (0.63–0.90) 54 / 13,701 0.71 (0.52–0.97) 45 / 13,710 0.67 (0.48-0.94)
>55 64 / 3,560 0.85 (0.65–1.11) 22 / 3,602 0.81 (0.51–1.28) 17 / 3,607 0.71 (0.42-1.18)
P for trendc <0.001 0.088 <0.001
FTP, Full term pregnancy; OCs, Oral contraceptives; ICD-10, International Statistical Classification of Diseases Injuries and Causes of Death (10th revision)
aCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical postmenopausal (bilateral oophorectomy)), body mass
index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m2), physical activity index (inactive [Ref], moderately inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/
professional school, secondary school/longer education including university, or unknown), smoking status and intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/
day, former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40,
40+ years, unknown), and stratified by age (continuous) and study centre
bFTP includes live births and stillbirths
cP for trend-values are based on continuous variables: number of FTPs (1 to ≥10); age at menarche (≤8, 9–19, ≥20); age at menopause (<35, 35–60, >60)
dAmong parous women
eAmong parous women who had ever breastfed (sum of all FTPs)
fRestricted to participants who were never or former smokers, therefore models were adjusted for the same factorsa and a modified smoking status/intensity variable (never [Ref], former quit ≤10 years,
former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)
gDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use
hOf 22 total circulatory disease deaths, 13 were due to cerebrovascular disease, 2 to ischaemic heart disease, and 7 to other circulatory-related causes (n = 2 ‘Pulmonary embolism without mention of acute cor
pulmonale’, and one death for each cause ‘Essential (primary) hypertension’, ‘Other specified pulmonary heart diseases’, ‘Cardiac arrest, unspecified’, ‘Atrial fibrillation and flutter’ and ‘Phlebitis and thrombophlebitis of
other deep vessels of lower extremities’)
iAmong ever users of OCs
jAmong postmenopausal women; exclusions included participants from Sweden (no data for hysterectomy/oophorectomy), those who had a surgical menopause (hysterectomy and/or unilateral/bilateral
oophorectomy), or if information on surgical menopause was missing
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suggests that there may be residual confounding by factors
that influence the age of menopause [52].
In analyses of OC use, we observed a lower risk for
all-cause, total cancer, and circulatory disease mortality
with ever versus never use of OCs among non-smokers;
this finding is consistent with two studies [11, 12], but
not others [8–10] that observed no association between
OC use and mortality risk. In analyses of cerebrovascular
disease mortality among non-smokers, we observed a
non-significant lower risk of death in ever versus never
users of OCs, while there was a higher risk of death
among participants who reported current OC use at the
study baseline although the latter finding was based on
only 13 deaths. These results for current OC use con-
trast with previous reports of no association with risk of
cerebrovascular disease death among current or recent
users of OCs (use within <5 years) from the Nurses’
Health Study [9] and the Royal College of General Prac-
titioners’ Oral Contraception Study [11]. In the current
study, the participant’s mean age at recruitment was
50 years and most of the OC use reported at the study
baseline referred to former use that likely occurred at
least 10–15 years ago; these findings should be inter-
preted in this context. We also explored the relationship
between OC use and mortality separately for never/
former and current smokers; however, smoking history
was based on information at the study baseline and
therefore may not reflect the smoking habits at the time
that OCs were used. It has been reported that smoking
15+ cigarettes/day doubles the risk of all-cause mortality
[12] and our results suggested that the possible benefits
of OC use may not outweigh the harmful effects of
smoking [53].
Together, these results highlight the possibility that
hormonal mechanisms may explain the link between
parity, breastfeeding, OC use, and a later age at menar-
che with a lower mortality risk. A shared mechanism for
breastfeeding and OC use is that both may reduce en-
dogenous estradiol production [54, 55]. A study in
Finnish girls observed that having a later age at menar-
che was associated with lower estrogen levels [56, 57],
but this result was not confirmed in studies of adult
women [58, 59]. Although pregnancy raises serum estro-
gen levels, this is accompanied by elevated progesterone
levels which may offset the proliferative effects of estro-
gen [60]. In contrast, breastfeeding and OC use reduce
endogenous progesterone synthesis [55, 61]. Both parity
and OC use would lower gonadotropin levels, specific-
ally luteinizing hormone and follicle-stimulating hor-
mone [55, 62], and girls with a late age at menarche also
had reduced follicle-stimulating hormone levels [56]. On
the other hand, breastfeeding lowers luteinizing hor-
mone but increases follicle-stimulating hormone [54].
Our epidemiologic findings are not consistent with an
androgen-related mechanism because parity is expected
to increase, and OC use decrease, androgen and specific-
ally testosterone levels [60, 63], while inconsistent results
have been reported regarding the association between
the age at menarche and androgen levels in postmeno-
pausal women [64, 65]. Importantly, since most of these
hormonal changes were measured at or near the time that
these reproductive events occurred, additional studies are
needed to evaluate how these reproductive characteristics
may influence a woman’s long-term hormonal profile in
order to highlight potential mechanisms that may explain
the strong inverse associations between parity, breastfeed-
ing, OC use, and a delayed age at menarche with risk of
mortality that were observed in the current study.
Possible study limitations include the use of a single
assessment of reproductive exposures at the study base-
line; however, it is unlikely that reproductive characteris-
tics would change particularly among postmenopausal
women and, indeed, we observed similar results when
analyses were restricted to the subgroup of postmeno-
pausal women. Reproductive events that occurred many
years previously may be subject to recall issues which
could attenuate risk estimates towards the null; however,
since we observed similar results when restricting to
women who were postmenopausal at recruitment this
suggests that this was not a major issue in this study.
Although we accounted for important potential con-
founding variables such as BMI, smoking status, and
education level in the analysis, we cannot exclude the
possibility that other unmeasured factors, such as under-
lying differences in social class, may explain the ob-
served associations. Another possible limitation is that
the EPIC participants are not representative of the gen-
eral population and they may have different distributions
of risk factors, such as smoking and BMI, which may
limit the generalizability of these findings. However, in
support of our conclusions, many results were consistent
with previous smaller-scale studies. Finally, advantages
of this investigation include the representation of findings
across 10 European countries and the near complete
follow-up for vital status.
Conclusions
This analysis of >320,000 European women highlighted
several reproductive characteristics, including childbirth,
breastfeeding, later age at menarche, and use of OCs in
non-smokers, that may lower the risk of all-cause mortality.
Further studies are needed to confirm these findings and to
clarify the mechanisms that link these reproductive expo-
sures to mortality risk. With a better understanding of the
impact of reproductive characteristics on mortality risk,
these data may be used to assist in the development of clin-
ical strategies to improve the long-term health of women.
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